Rifampicin + Isoniazid + Pyrazinamide + Ethambutol

Generic Name

Rifampicin-Isoniazid-Pyrazinamide-Ethambutol

Other Names

• RIPE Therapy

Drug Class

• Antituberculosis Agents

Chemical Formula

Molecular Weight

Mechanism of Action

• Each component acts on different stages of the mycobacterial cell wall synthesis.

Indications

• Treatment of active tuberculosis caused by susceptible strains of mycobacteria.

Common Dosage Forms

• Tablet
• Capsule

Typical Dosage

• One tablet or capsule daily for a specific duration as determined by a healthcare provider.

Pediatric Dosage

• Dosage adjustment may be required based on weight and age.

Geriatric Dosage

• Dosage adjustment may be necessary due to age-related changes in metabolism.

Side Effects

• Nausea
• Vomiting
• Loss of appetite
• Abdominal pain
• Headache
• Dizziness

Contraindications

• Hypersensitivity to any component
• Severe hepatic impairment

Pregnancy Category

• May be used in pregnancy with caution under healthcare provider supervision.

Lactation Safety

• Limited data available, caution advised while breastfeeding.

Drug Interactions

• May interact with other antituberculosis agents, antivirals, rifamycins.

Overdose Symptoms

• Nausea
• Vomiting
• Liver toxicity

Antidote for Overdose

• No specific antidote, supportive treatment for symptoms.

Storage Conditions

• Store in a cool, dry place away from direct sunlight.

Pharmacokinetics

• Absorption: Well-absorbed orally
• Distribution: Distributed widely in body tissues
• Metabolism: Metabolized in the liver
• Excretion: Excreted primarily in the urine

Precautions

• Monitor liver function tests during therapy
• Caution in patients with hepatic impairment

Warnings

• Risk of hepatotoxicity
• May cause drug-induced hepatitis

Others

• Ensure adequate monitoring during therapy.